Please ensure Javascript is enabled for purposes of website accessibility

Moderna to Begin Developing a Coronavirus Vaccine

By Todd Campbell - Jan 23, 2020 at 10:44AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotechnology company has been awarded a grant from the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine for the fast-spreading illness.

Thanks to a grant from the Coalition for Epidemic Preparedness Innovations (CEPI), the hunt for a vaccine to help stop the spread of a newly identified, fast-moving coronavirus is under way at Moderna (MRNA 0.70%), a clinical-stage biotech company. Currently, the company has five vaccines under development, including one targeting the Zika virus.

A woman wearing a face mask.


A family of viruses that can be passed between humans and animals, coronanaviruses can can cause life-threatening respiratory illness, including pneumonia. Since these viruses can evolve into new strains, they can be tough to treat. Some examples of the virus include Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS), which are two coronaviruses that pose challenges for healthcare professionals. 

On January 7, 2020, Chinese researchers reported a new coronavirus strain -- 2019-nCoV -- which has caused pneumonia in multiple people in Wuhan City in the Hubei Province of China. Since then, over 550 cases of 2019-nCoV have been identified, including one in the United States. So far, the coronavirus has resulted in 17 deaths, prompting China to invoke travel restrictions and researchers to ramp efforts to develop a vaccine for it.

Moderna hopes to tackle 2019-nCoV by leveraging its research into messenger RNA (mRNA), the instructions used by cells to make proteins. By tinkering with mRNA, Moderna hopes to cause cells to produce viral antigens, triggering an immune response in patients that can help to prevent the more infection. If Moderna succeeds, then the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) will test its vaccine in Phase 1 clinical studies. However, it may be a while before we find out if Moderna's vaccine is effective, because it can take years to conduct the clinical research necessary to secure Food and Drug Administration approval.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
$144.27 (0.70%) $1.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.